Details
Stereochemistry | ACHIRAL |
Molecular Formula | C19H16F2N8O2 |
Molecular Weight | 426.3795 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
COC(=O)NC1=C(N)N=C(N=C1N)C2=NN(CC3=CC=CC=C3F)C4=NC=C(F)C=C24
InChI
InChIKey=QZFHIXARHDBPBY-UHFFFAOYSA-N
InChI=1S/C19H16F2N8O2/c1-31-19(30)25-14-15(22)26-17(27-16(14)23)13-11-6-10(20)7-24-18(11)29(28-13)8-9-4-2-3-5-12(9)21/h2-7H,8H2,1H3,(H,25,30)(H4,22,23,26,27)
Molecular Formula | C19H16F2N8O2 |
Molecular Weight | 426.3795 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Approval Year
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 07:53:18 UTC 2023
by
admin
on
Sat Dec 16 07:53:18 UTC 2023
|
Record UNII |
LV66ADM269
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C29707
Created by
admin on Sat Dec 16 07:53:18 UTC 2023 , Edited by admin on Sat Dec 16 07:53:18 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
LV66ADM269
Created by
admin on Sat Dec 16 07:53:18 UTC 2023 , Edited by admin on Sat Dec 16 07:53:18 UTC 2023
|
PRIMARY | |||
|
Vericiguat
Created by
admin on Sat Dec 16 07:53:18 UTC 2023 , Edited by admin on Sat Dec 16 07:53:18 UTC 2023
|
PRIMARY | |||
|
142432
Created by
admin on Sat Dec 16 07:53:18 UTC 2023 , Edited by admin on Sat Dec 16 07:53:18 UTC 2023
|
PRIMARY | |||
|
9805
Created by
admin on Sat Dec 16 07:53:18 UTC 2023 , Edited by admin on Sat Dec 16 07:53:18 UTC 2023
|
PRIMARY | |||
|
DB15456
Created by
admin on Sat Dec 16 07:53:18 UTC 2023 , Edited by admin on Sat Dec 16 07:53:18 UTC 2023
|
PRIMARY | |||
|
LV66ADM269
Created by
admin on Sat Dec 16 07:53:18 UTC 2023 , Edited by admin on Sat Dec 16 07:53:18 UTC 2023
|
PRIMARY | |||
|
DTXSID001318361
Created by
admin on Sat Dec 16 07:53:18 UTC 2023 , Edited by admin on Sat Dec 16 07:53:18 UTC 2023
|
PRIMARY | |||
|
100000175190
Created by
admin on Sat Dec 16 07:53:18 UTC 2023 , Edited by admin on Sat Dec 16 07:53:18 UTC 2023
|
PRIMARY | |||
|
C152862
Created by
admin on Sat Dec 16 07:53:18 UTC 2023 , Edited by admin on Sat Dec 16 07:53:18 UTC 2023
|
PRIMARY | |||
|
1350653-20-1
Created by
admin on Sat Dec 16 07:53:18 UTC 2023 , Edited by admin on Sat Dec 16 07:53:18 UTC 2023
|
PRIMARY | |||
|
54674461
Created by
admin on Sat Dec 16 07:53:18 UTC 2023 , Edited by admin on Sat Dec 16 07:53:18 UTC 2023
|
PRIMARY | |||
|
2475830
Created by
admin on Sat Dec 16 07:53:18 UTC 2023 , Edited by admin on Sat Dec 16 07:53:18 UTC 2023
|
PRIMARY | |||
|
GH-146
Created by
admin on Sat Dec 16 07:53:18 UTC 2023 , Edited by admin on Sat Dec 16 07:53:18 UTC 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT | |||
|
TRANSPORTER -> SUBSTRATE |
|
||
|
BINDER->LIGAND |
Protein binding (primarily to serum albumin) of vericiguat is about 98%.
BINDING
|
||
|
TRANSPORTER -> SUBSTRATE |
|
||
|
METABOLIC ENZYME -> SUBSTRATE |
|
||
|
METABOLIC ENZYME -> SUBSTRATE |
|
||
|
TARGET -> ACTIVATOR |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
Volume of Distribution | PHARMACOKINETIC |
|
IN HEALTHY SUBJECTS PHARMACOKINETIC |
|
||
Tmax | PHARMACOKINETIC |
|
FASTED STATE PHARMACOKINETIC |
|
||
ABSOLUTE BIOAVAILABILITY | PHARMACOKINETIC |
|
FED CONDITION PHARMACOKINETIC |
|
||
Biological Half-life | PHARMACOKINETIC |
|
IN PATIENTS WITH HEART FAILURE NUCLEIC ACID FEATURE |
|
||
Tmax | PHARMACOKINETIC |
|
HIGH-FAT, HIGH-CALORIE MEAL PHARMACOKINETIC |
|
||